Reproduction of any material whether by photocopying or storing in any medium by electronic means or otherwise is prohibited without prior written consent.

Slides:



Advertisements
Similar presentations
© 2013 Sri U-Thong Limited. All rights reserved. This presentation has been prepared by Sri U-Thong Limited and its holding company (collectively, “Sri.
Advertisements

© 2014 Microsoft Corporation. All rights reserved.
©2010 ExxonMobil. To the extent the user is entitled to disclose and distribute this document, the user may forward, distribute, and/or photocopy this.
Innovations in Structured Products October 25, 2010 An Innovator’s Dilemma?
Product Liability When goods cause injury, there is a question of product liability. There are three main issues related to product liability cases: –
Jul The New Geant4 License J. Perl The New Geant4 License Makes clear the user’s wide- ranging freedom to use, extend or redistribute Geant4, even.
1 Copyright © 2012 Mahindra & Mahindra Ltd. All rights reserved. 1 Change Management – Process and Roles.
1 Copyright © 2012 Mahindra & Mahindra Ltd. All rights reserved. 1 Hybrid Projects - Defect Management - Process and Roles.
Chapter 25 Warranties McGraw-Hill/Irwin Copyright © 2012 by The McGraw-Hill Companies, Inc. All rights reserved.
Intel® Education Learning in Context: Science Journal Intel Solutions Summit 2015, Dallas, TX.
QBE European Operations The QBE Foundation: Giving something back.
Chapter 12 Supply Law and Ethics McGraw-Hill/Irwin Purchasing and Supply Management, 13/e © 2006 The McGraw-Hill Companies, Inc., All Rights Reserved.
Anticipated 2008 Generic Launches JULY 2008 David Harding, API Intelligence, Thomson Reuters Source: FDA, NEWPORT HORIZON PREMIUM TM © THOMSON REUTERS.
Copyright 2011, Atmel December, 2011 Atmel ARM-based Flash Microcontrollers 1 1.
Reproduction of any material whether by photocopying or storing in any medium by electronic means or otherwise is prohibited without prior written consent.
PRODUCTIVITY – THE PICTURE FOR THE UK & THE WEST MIDLANDS SUSTAINING COMPETITIVENESS CONFERENCE – THE BELFRY RHYS HERBERT SENIOR ECONOMIST 6 JULY 2012.
MESSAGING IN THE MEDIA TOP 10 DRUGS BASED ON CREDIBILITY INDEX IN THE LITERATURE JOHN KNAPP, DIRECTOR OF ANALYTICS MAY 2009 Your use of these materials.
End User License Agreement Permission to use and redistribute this Document is granted, provided that (1) the below copyright notice appears in all copies.
Reproduction of any material whether by photocopying or storing in any medium by electronic means or otherwise is prohibited without prior written consent.
Therapeutic area breakdown of lead projects in development for first launch in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM ©
IBIS-AMI and Direction Decisions
Proportion of biotech-derived active substances in development for first launch 31st December APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
Reproduction of any material whether by photocopying or storing in any medium by electronic means or otherwise is prohibited without prior written consent.
National Alliance for Medical Image Computing Licensing in NAMIC 3 requirements from NCBC RFA (paraphrased)
Proportion of total R&D expenditure by therapeutic area in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS Your.
Click to add text © 2012 IBM Corporation 1 InfoSphere Streams Streams Console Applications InfoSphere Streams Version 3.0 Warren Acker InfoSphere Streams.
Oracle Fusion Applications 11gR1 ( ) Functional Overview (L2) Manage Inbound Logistics (L3) Manage and Disposition Inventory Returns.
Global R&D expenditure, development times, global pharmaceutical sales and new molecular entity output MARCH 2008 SOURCE: CMR INTERNATIONAL.
2005/2006 Expenditure on biotech derived entities had remained constant APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS.
Number of pharmaceutical patent applications and granted patents for 5 major patent issuing authorities JUNE 2008 SOURCE: DERWENT WORLD PATENTS.
INTEL CONFIDENTIAL Intel® Smart Connect Technology Remote Wake with WakeMyPC November 2013 – Revision 1.2 CDI/IBP #:
Regulatory approval times between submission and marketing authorization approval APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM.
For Oracle employees and authorized partners only. Do not distribute to third parties. © 2008 Oracle Corporation – Proprietary and Confidential.
Availability of High-Quality API for India, China and Rest of World MARCH 2008 David Harding, API Intelligence, Thomson Reuters Source: NEWPORT HORIZON.
1 Certification Program User Management 01 - Roles.
End User License Agreement Permission to use and redistribute this Document is granted, provided that (1) the below copyright notice appears in all copies.
Allocation of R&D expenditure in 2005 between chemical entity and biological or biotech active substances APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
Copyright © 2010 South-Western Legal Studies in Business, a part of South-Western Cengage Learning. and the Legal Environment, 10 th edition by Richard.
Can Newspapers Survive Paul Harris / London / October 2012.
Reproduction of any material whether by photocopying or storing in any medium by electronic means or otherwise is prohibited without prior written consent.
The secure site rendering issue (all navigation crushed together as a list at the top of the page) is a compatibility issue with Internet Explorer only.
Copyright © 2012, Oracle and/or its affiliates. All rights reserved. Oracle Proprietary and Confidential. 1.
1 Combining two subject areas in an Alma Analytics Report Yoel Kortick Senior Librarian.
Spring 2016 ICC Meeting – Subcommittee F Estimating the Value / Benefit of Diagnostics 1 of 3 – Perhaps? Josh Perkel and Nigel Hampton NEETRAC.
Use this title slide only with an image Session 1: What Is IP Dr. Jim S. Zeng May 8, 2014.
Connectivity to bank and sample account structure
RaboDirect Financial Health Barometer 2016
Overview of Acquisition Claiming in Alma
CHAPTER 22 Warranties and Product Liability.
<Insert Picture Here>
How to configure and use the Holdings record Accession Number
Credit Risk Management Mark Schulz Lugano, 22 September 2016
BIOLOGY / CHEMISTRY CITATIONS GROWTH
Parallelspace PowerPoint Template for ArchiMate® 2.1 version 1.1
Parallelspace PowerPoint Template for ArchiMate® 2.1 version 2.0
Automation in an XML Authoring Environment
Mark Bennett, Head of Agribusiness, ANZ
Messaging in the Media TOP 10 AUDIENCES BY THERAPY AREA
2006 Revenue continued to depend on a relatively small number of products APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS.
VII Encuentro de Usuarios GRUEXCOL
Find the Problems with the Provisions May 11, 2016 Presented By:
Environmental Upgrade Finance
Motivation for 36OU Open Rack
Copyright 2017 © Condry & Associates, Inc. + All rights reserved *
TITLE Source: Footnotes:. TITLE Source: Footnotes:
© 2013 Sri U-Thong Limited. All rights reserved
3M™ Universal Cover Tape (UCT) 2688A application procedure
2019 MEDICARE AGE-IN STUDY SENIOR MARKET INSIGHTS SERVICE Part IV
Presentation transcript:

Reproduction of any material whether by photocopying or storing in any medium by electronic means or otherwise is prohibited without prior written consent of Infineum International Limited. © Copyright INFINEUM INTERNATIONAL LIMITED All rights reserved See the legal disclaimer notice on "INFINEUM", "DOBANAX", "PARATAC", "SYNACTO", "VEKTRON", and the corporate mark comprising the interlocking ripple device are trademarks of Infineum International Ltd. “VISTONE” is a trademark of Exxon Mobil Corporation used under licence by Infineum International Limited. P Volatility Parameters Wangkan Lin February 5, 2008

© Copyright INFINEUM INTERNATIONAL LIMITED 2006 Ca Balance in IIIG – Negative Mass Loss mThe negative mass loss in IIIG mass balance occurred mainly in the first 20-Hour testing. mIn about 37% of the reference tests, there was more Ca after first 20-hour testing than the start of the testing. mThe Ca is calculated simply by the product of mass times concentration. In these Ca deficit tests, * < *

© Copyright INFINEUM INTERNATIONAL LIMITED 2006 Ca Balance in IIIG – Negative Mass Loss mFor some reason, the loss of Ca in the first 20 Hour of testing is much smaller than the loss during the rest of the test. qOn average, the first 20-Hour testing loses 0.2 gram less Ca than any other 20-Hr testing period mThe small Ca loss during the first 20-Hour can swing it to negative value in many of the tests.

© Copyright INFINEUM INTERNATIONAL LIMITED 2006 Ca Balance in IIIG – Negative Mass Loss mOn average, the first 20-Hour testing loses 0.2 gram less Ca than any other 20-Hr testing period. mThis translates to about 170 – 270 ml less oil loss by liquid form.

© Copyright INFINEUM INTERNATIONAL LIMITED 2006 What caused Negative Ca Mass Loss? mWhy is the volume of the first 20-hour oil loss by liquid about at least 200 ml less than other 20-hour testing period? qWe believe the oil loss by liquid is usually tied to the oil film left on the surface of inside the cylinders. qOnly four numbers are used for Ca balance uCa Concentration at Start uCa Concentration at 20Hr uVolume at Start: (5500 – 236) ml uVolume after 20 Hour testing Ca Loss = Ca_20Hr * V_20Hr – Ca_0Hr * V_0Hr

© Copyright INFINEUM INTERNATIONAL LIMITED 2006 What caused Negative Ca Mass Loss? Conclusion: The negative Ca mass loss is related to the Oil level measurements at 20 Hr. Note: the oil volume at 20Hr is not an absolute measurement. It is based on the difference of oil level between 0Hr and 20Hr. Volume Delta

© Copyright INFINEUM INTERNATIONAL LIMITED 2006 Mass Balance in Sequence IIIG Total Ca Loss Liquid P Loss Liquid Oil Loss P Loss by VolatilityTotal P Loss Ca does not evaporate P Concentration Difference Volume Delta Effect?

© Copyright INFINEUM INTERNATIONAL LIMITED 2006 Mass Balance in Sequence IIIG Total P Loss = V t P t – V 0 P 0 Total Ca Loss = V t Ca t – V 0 Ca 0 P Volatility Loss = Total P Loss – Liquid P Loss Liquid P Loss = (V t Ca t – V 0 Ca 0 ) * P/Ca = (Ca 0 P t – Ca t P 0 ) * (V t + V 0 ) / (Ca t + Ca 0 ) An quantity which is sensitive to Volume Delta An quantity which is NOT sensitive to Volume Delta

© Copyright INFINEUM INTERNATIONAL LIMITED 2006 The information contained in this document is based upon data believed to be reliable at the time of going to press and relates only to the matters specifically mentioned in this document. Although Infineum has used reasonable skill and care in the preparation of this information, in the absence of any overriding obligations arising under a specific contract to supply goods or services,: no representation, warranty (express or implied), or guarantee is made as to the suitability, accuracy, reliability of completeness of the information; nothing in this document shall reduce the user’s responsibility to satisfy itself as to the suitability, accuracy, reliability, and completeness of such information for its particular use; there is no warranty against intellectual property infringement; and Infineum shall not be liable for any loss, damage or injury that may occur from the use of this information other than death or personal injury caused by its negligence. No statement shall be construed as an endorsement of any product or process. For greater certainty, before use of information contained in this document, particularly if it is used for a purpose or under conditions which are abnormal or not reasonably foreseeable, it must be reviewed with the supplier of such information.  Copyright INFINEUM INTERNATIONAL LIMITED All rights reserved.